Izland -
izlandi -
LYFJASTOFNUN (Icelandic Medicines Agency)
pranolol tafla 40 mg
actavis group ptc ehf. - propranololum hýdróklóríð - tafla - 40 mg
Izland -
izlandi -
LYFJASTOFNUN (Icelandic Medicines Agency)
pranolol tafla 80 mg
actavis group ptc ehf. - propranololum hýdróklóríð - tafla - 80 mg
Izland -
izlandi -
LYFJASTOFNUN (Icelandic Medicines Agency)
attentin tafla 20 mg
medice arzneimittel pütter gmbh & co. kg* - dexamfetaminum súlfat - tafla - 20 mg
Izland -
izlandi -
LYFJASTOFNUN (Icelandic Medicines Agency)
isoptin retard forðatafla 120 mg
viatris aps - verapamilum hýdróklóríð - forðatafla - 120 mg
Izland -
izlandi -
LYFJASTOFNUN (Icelandic Medicines Agency)
diltiazem hcl alvogen (dilmin) forðatafla 120 mg
alvogen ehf. - diltiazemum hýdróklóríð - forðatafla - 120 mg
Izland -
izlandi -
LYFJASTOFNUN (Icelandic Medicines Agency)
attentin tafla 10 mg
medice arzneimittel pütter gmbh & co. kg* - dexamfetaminum súlfat - tafla - 10 mg
Izland -
izlandi -
LYFJASTOFNUN (Icelandic Medicines Agency)
attentin tafla 5 mg
medice arzneimittel pütter gmbh & co. kg* - dexamfetaminum súlfat - tafla - 5 mg
Európai Unió -
izlandi -
EMA (European Medicines Agency)
hemangiol
pierre fabre medicament - própranólól hýdróklóríð - hemangioma - betablokkar - hemangiol is indicated in the treatment of proliferating infantile haemangioma requiring systemic therapy: , life- or function-threatening haemangioma,, ulcerated haemangioma with pain and/or lack of response to simple wound care measures,, haemangioma with a risk of permanent scars or disfigurement. , it is to be initiated in infants aged 5 weeks to 5 months.
Izland -
izlandi -
LYFJASTOFNUN (Icelandic Medicines Agency)
sotalol viatris (sotalol mylan) tafla 40 mg
viatris limited - sotalolum hýdróklóríð - tafla - 40 mg
Izland -
izlandi -
LYFJASTOFNUN (Icelandic Medicines Agency)
sotalol viatris (sotalol mylan) tafla 80 mg
viatris limited - sotalolum hýdróklóríð - tafla - 80 mg